News

Higher dose of pneumococcal vaccine improves antibody response in patients receiving rituximab for ANCA-associated vasculitis

By 68 views
0
Research scientist using digital tablet to browse internet and find biochemistry discovery. Female chemist working with device to create pharmaceutical cure, microbiology experiment.

New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

Study: No significant difference in cancer risk in rheumatology patients with history of malignancy taking DMARDs

Previous article

Study helps understand the basis of sex differences in SARS-CoV-2 infection

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in News